Given that it might well be that MHC-restricted anti-CSPG4 TCR are more sensitive in contrast to anti-CSPG4 CAR-T cells, on-target off-tumor toxicity must be critically assessed before any clinical evaluation of this TCRs is initiated. This evidence concerns the gene CSPG4 and neoplasm.